GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuPharma PLC (STU:25I) » Definitions » Deferred Policy Acquisition Costs

ImmuPharma (STU:25I) Deferred Policy Acquisition Costs


View and export this data going back to 2012. Start your Free Trial

What is ImmuPharma Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


ImmuPharma (STU:25I) Business Description

Industry
Traded in Other Exchanges
Address
One Bartholomew Close, London, GBR, EC1A 7BL
ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus and a life-threatening autoimmune disease.